Recipharm secures major additional grant to develop AI-enabled manufacturing technologies
Development of an AI-enabled simulator and process control platform, to speed up process development, cut costs and improve manufacturing efficiency
Advertisement
Recipharm announced that its Advanced Bio division has been awarded a major additional grant from The Gates Foundation. The initial grant from the foundation focused on advancing Process Analytical Technologies (PAT) in xRNA manufacturing, while the new funding will support integrating artificial intelligence (AI) into PAT to enable continuous manufacturing of xRNA vaccines. The initiative aims to accelerate the development of a digital, next-generation manufacturing platform that reduces production costs and improves vaccine access for LMICs.
Vikas Gupta, President, Recipharm Advanced Bio, said: “This grant from The Gates Foundation enables Recipharm Advanced Bio to demonstrate how AI, coupled with PAT, can help close the global access gap. Smarter, faster and more cost-effective manufacturing can make life-affirming medicines available to more people around the world. At Recipharm, we are leading with innovation to build next-generation manufacturing platforms that ultimately benefit patients by delivering advanced therapies more efficiently and affordably.”
The project includes development of an AI-enabled manufacturing simulator which allows for instant process development and virtual experimentation, eliminating the need for extensive lab work. This approach could significantly reduce development costs and timelines for vaccines across modalities, including monoclonal antibodies (mAbs).
Additional work will focus on predictive maintenance and real-time analytics. By combining historical data with machine learning, the platform will be able to predict outcomes, identify risks and uncover opportunities. The project will also look at integrating AI-driven process controls into existing manufacturing systems. As the AI models learn from new data, they will improve process performance, efficiency and reliability.
Recipharm brings deep expertise and a proven track record across advanced therapies, including plasmid DNA, xRNA, lipid nanoparticles, viral vectors and sterile fill and finish. With end-to-end capabilities from process development through clinical and commercial manufacturing, Recipharm offers a “bench to clinic” pathway within a single CDMO network.
At its Watertown, MA site, Recipharm can deliver the full value chain for nucleic acid modalities, including plasmid DNA, xRNA, lipid nanoparticle formulation, and sterile fill and finish. The company partners closely with customers, fast-tracking development, minimising cost and delivering high-quality products.
Other news from the department business & finance
